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Abstract
Objectives To investigate arterial spin-labelling (ASL) cere-
bral blood flow (CBF) changes in predementia stages of
Alzheimer’s disease (AD).
Methods Data were obtained from 177 patients with
subjective complaints, mild cognitive impairment and
AD from the Amsterdam Dementia Cohort. AD stages
were based on diagnosis and cerebrospinal fluid bio-
markers amyloid-β (Aβ) and total-tau (tau). General-
linear-models were used to assess relationships between
AD stages and total and regional CBF, correcting for
age and sex.
Results Decreasing CBF was related to more advanced AD
stages in all supratentorial regions (p for trend < 0.05). Post-
hoc testing revealed that CBF was lower in AD com-
pared to controls and stage-1 predementia patients (i.e.
abnormal Aβ and normal tau) in temporal and parietal
regions, and compared to stage-2 predementia patients
(i.e. abnormal Aβ and tau) in temporal regions. CBF
values of stage-2 predementia patients were numerically
in between those of stage-1 predementia patients and
AD.
Conclusion The continuing decrease of CBF along the con-
tinuum of AD indicates the potential of ASL-CBF as a mea-
sure for disease progression.
Key Points
• Decreasing CBF relates to more advanced AD stages in all
supratentorial regions.
• The reduction of CBF does not reach a bottom level.
• ASL-CBF has potential as a measure for disease progression
in AD.
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Introduction
The first pathological signs of Alzheimer’s disease (AD), in
the form of amyloid-β1-42 (Aβ) plaque deposition, can be
detected up to decades before clinical symptoms first occur
[1]. However, these very early pathological signs of AD do
not correlate with disease progression in clinical AD [2]. Neu-
ronal and synaptic function measures, such as CSF total-tau
(tau) and 18F-fluorodeoxyglucose positron emission tomogra-
phy (FDG-PET), are thought to start changing later on in the
disease process. Moreover, they are thought to relate to cog-
nitive performance, and to continue to change along the dis-
ease process, which might make them more suitable for mon-
itoring disease progression [2–4].
Arterial spin-labelling (ASL) is a functional magnetic res-
onance imaging (MRI) technique that measures cerebral blood
flow (CBF) by using magnetically labelled arterial blood that
flows through the carotid and vertebral arteries as an endoge-
nous contrast medium. Important advantages of ASL are its
non-invasiveness and short acquisition time at higher magnet-
ic field strengths, which allows routine clinical application in
the workup of dementia when ASL is added to the standard
dementia imaging protocol.
Recently, new diagnostic and scientific criteria for clinical
AD and its predementia stages have been introduced by the
National Institute on Aging and the Alzheimer’s Association
(NIA-AA) [5–7]. For scientific purposes, these criteria offer
the possibility of subdividing subjects with normal cognition,
such as patients with subjective complaints (SC), and patients
with mild cognitive impairment (MCI) into different
predementia AD stages using Aβ and neuronal injury
biomarkers.
In a previous study we showed that ASL discriminated AD
patients from controls, and that regional CBF values of MCI
patients were numerically in between those of controls and
AD patients [8]. In the current study we aimed to further
investigate CBF along the course of AD, by studying CBF




In this cross-sectional study we included 275 patients (107
AD patients, 64 MCI patients and 104 SC patients) from the
memory clinic-based Amsterdam Dementia Cohort. All pa-
tients visited our memory clinic between October 2010 and
June 2012, underwent brain MRI according to the dementia
protocol described below, and had cerebrospinal fluid (CSF)
available for analysis of CSF biomarkers. All patients
underwent a standard dementia screening that included
medical history, physical and neurological examinations,
screening laboratory tests, lumbar puncture, neuropsycholog-
ical testing and brain MRI. Clinical diagnosis was established
by consensus in a multidisciplinary team. AD patients met the
NINCDS-ADRDA criteria for probable AD [9], and also met
the core clinical criteria for probable AD proposed by the
NIA-AA workgroup [6]. MCI patients fulfilled the Petersen
criteria [10, 11]. Patients were considered to have subjective
complaints when clinical investigations and neuropsycholog-
ical test performance were normal. Patients with a history of
head trauma or intracranial tumours were excluded. The local
Institutional Review Board approved the study. All patients
provided written informed consent.
MRI acquisition
MRI examinations were performed on a 3T whole body MR
system (SignaHDxt, GE Medical Systems Milwaukee, WI,
USA) using an 8-channel head coil. Structural images includ-
ed a sagittal 3D T1-weighted sequence (IR-FSPGR, echo
time=3.0ms, repetition time=7.8ms, inversion time=450ms,
flip angle=12°, matrix 256×256, 176 slices, voxel size
1×0.9×0.9mm) for anatomical information, and a sagittal 3D
fluid attenuated inversion recovery (FLAIR) sequence
(CUBE, echo time=123.6 ms, repetition time=8000 ms, inver-
sion time=2351 ms, echo-train length=230, acquisition matrix
224x224, reconstruction matrix 256×256, 132 slices, voxel
size 1.2×1×1mm) to determine the severity of white matter
hyperintensities (WMH) using the Fazekas scale [12].
Pseudo-continuous ASL (PCASL) [13, 14] perfusion images
(3D-FSE acquisition with background suppression, post-label
delay 2.0s, echo time=9 ms, repetition time=4.8 s, spiral read-
out eight arms × 512 samples; 36×5.0mm axial slices,
3.2×3.2mm in-plane resolution, reconstructed pixel size
1.7×1.7mm, acquisition time 4 min) were calculated using a
single-compartment model [15] after the subtraction of la-
belled from control images. More details are provided in an
earlier study by Binnewijzend et al. [8].
Pre-processing and MRI data analysis
Both T1-weighted and PCASL images were corrected for gra-
dient non-linearities in all three directions. Further data anal-
yses were carried out using FSL (version 4.1; http://www.
fmrib.ox.ac.uk/fsl). Pre-processing of T1 images consisted of
non-brain tissue removal [16], linear registration to standard
space [17] and tissue segmentation [18] yielding partial vol-
ume estimates. Gray matter volumes, normalized for subject
head size (NGMV), were calculated with the SIENAX soft-
ware tool [16]. The CBF maps [8] were linearly registered to
the brain-extracted T1 images. The brain mask was used to
calculate uncorrected mean whole brain CBF. Partial volume
estimates were transformed to the ASL data space and used in
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a regression algorithm [19], using a Gaussian kernel of 9.5-
mm full width at half maximum, to create partial volume
corrected (PVC) cortical CBF maps. Partial volume estimates
were subsequently used as a weighting factor to calculate
mean cortical CBF. The MNI152 atlas and the Harvard-
Oxford cortical atlas (both part of FSL) were used to create
regions of interest (ROIs) of the frontal, temporal, parietal,
precuneus and posterior cingulate (PPC), occipital and cere-
bellar brain areas, to extract mean regional uncorrected and
PVC cortical CBF values.
CSF analysis
CSF was obtained by lumbar puncture of the L3/L4 or L4/L5
intervertebral space, using a 25-gauge needle, and collected
via a syringe in 12-ml polypropylene tubes (Sarstedt). A small
amount of CSF was used for routine analysis, including total
cells (leucocytes and erythrocytes), total protein and glucose.
Within 2 hours, CSF samples were centrifuged at 2100 × g for
10 min at 4°C and the supernatant was transferred into a sec-
ond polyprolylene tube (Sarstedt) and stored at −20°C until
AD biomarker analysis. CSF amyloid-β1-42 and total-tau were
measured with Innotest (Innogenetics) sandwich enzyme-
linked immunosorbent assay as described previously [20].
The team involved in the CSF analysis was not aware of the
clinical diagnosis.
Definition of AD stages
Patients were divided into AD stages based on the combina-
tion of both syndrome diagnosis and CSF biomarker values,
considering Aβ below 550 ng/L, and tau above 375 ng/L as
abnormal (i.e. positive) [20]. For AD, only patients with a
high likelihood of having an AD pathophysiology were in-
cluded. AD patients with normal Aβ and/or tau values (n=
41) were excluded. For predementia stages, we collapsedMCI
and preclinical stages to overall predementia AD stages to
ensure sufficient power. Only patients fitting in the biomarker
stages were included. Therefore, MCI patients with normal
Aβ values (n=42) and SC patients with normal Aβ and ab-
normal tau values (n=13) were excluded.
Subsequently, MR images of all patients were visually
inspected. One AD patient was excluded because registration
of the ASL images to T1 images failed, possibly due to sub-
optimal quality of the ASL images. One other AD patient was
excluded because of haemochromatosis.
This resulted in the following four study groups: 80 SC
patients with normal CSF Aβ and tau (controls, stage 0), 13
predementia patients (six SC, seven MCI) with abnormal CSF
Aβ and normal CSF tau (stage 1), 20 predementia patients
(five SC, 15 MCI) with abnormal CSF Aβ and tau (stage 2)
and 64 clinically demented AD patients with abnormal CSF
Aβ and tau (stage 3).
Statistics
Statistical analyseswere performed using IBMSPSS Statistics
for Mac (Version 19.0., IBM Corp., Armonk, NY, USA). For
continuous measures, differences between groups were
assessed using one-way analyses of variance (ANOVA) with
post-hoc Bonferroni tests to correct for multiple comparisons.
A chi-squared test was used to compare frequency distribu-
tions of sex in all study groups, and syndrome diagnosis (i.e.
SC or MCI) in the predementia groups. General linear models
(GLMs) were used to assess the relationships between AD
stages (entered as continuous measure to assess the dose-
response effect) and total and regional uncorrected and PVC
cortical CBF, correcting for the effect of age and sex. Post-
hoc, univariate GLMs (total CBF) and multivariate GLMs
(regional CBF) with Bonferroni tests were performed to com-
pare CBF values of different AD stages, correcting for the
effect of age and sex (model 1), and additionally for WMH
(model 2). Linear regression analyses were performed across
groups and within the study groups to assess relationships
between CBF (independent variable) and cognition, using
MMSE-scores (dependent variable). Age and sex, and addi-
tionally WMH, were entered into the model as covariates.
Results
Demographics, MRI findings and CSF results are presented in
Table 1. Stage-2 predementia patients and stage-3 AD demen-
tia patients were older than controls. Patients with AD demen-
tia had lower MMSE-scores compared to all the other groups.
Stage-2 predementia patients and AD dementia patients had
moreWMH than controls. NGMVwas lower in AD dementia
patients compared to controls and stage-1 predementia pa-
tients, and NGMV was lower in stage-2 predementia patients
compared to controls. Finally, by definition, CSF Aβ was
lower in all groups compared to controls, and CSF tau was
higher in AD dementia patients and stage-2 predementia pa-
tients compared to controls and stage-1 predementia patients.
Total CBF differences
With increasing AD stage, both uncorrected whole brain
and PVC cortical CBF decreased (p for trend < 0.01)
(Table 2). Post-hoc tests showed that AD dementia pa-
tients had lower uncorrected whole brain CBF compared
to controls and stage-1 predementia patients, and lower
PVC cortical CBF compared to controls. There were no
differences in CBF between predementia patients and
controls. Additional correction for WMH did not change
the group differences.
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Table 1 Patient characteristics,
magnetic resonance imaging
(MRI) findings and cerebrospinal
fluid (CSF) data
Control Predementia AD
Stage 0 Stage 1 Stage 2 Stage 3
Number 80 13 20 64
Age (y)a 58±9 64±7 66±5* 66±7*
Females, no. (%) 31 (39) 5 (39) 9 (45) 34 (53)
Diagnosis (MCI), no. (%) - 7 (54) 15 (75) -
MMSEa,b 28±2 28±2 26±2 21±4*,¥,§
WMHa 0.6±0.7 1.2±0.9 1.2±0.8* 1.1±0.8*
NGMV (mL)a 780±53 770±55 733±63* 711±46*,¥
CSFAβ1-42(ng/L)
a 986±188 444±89* 442±70* 459±68*
CSF tau (ng/L)a 220±73 292±75 782±370*,¥ 796±340*,¥
a Data are given as mean ± standard deviation
bMini Mental State Examination (MMSE) scores of two controls were excluded because they were obtained by
means of an interpreter
Stage 0: Aβ-/tau- patients with subjective complaints (SC), Stage 1: Aβ+/tau- patients with SC and mild
cognitive impairment (MCI), Stage 2: Aβ+/tau+ patients with SC andMCI, Stage 3: Aβ+/tau+ patients with AD
*p<0.05 compared to controls, ¥ p<0.05 compared to stage-1 predementia patients, § p<0.05 compared to stage-
2 predementia patients
AD Alzheimer’s disease,WMH white matter hyperintensities (based on Fazekas-score), NGMV normalized grey
matter volume
Table 2 Region-of-interest based
cerebral blood flow (CBF) values Control Predementia AD
Stage 0 Stage 1 Stage 2 Stage 3
Uncorrected whole brain CBF*** 32±5 32±5 30±5 28±5a,b
PVC cortical CBF** 48±8 48±7 45±8 43±8a
Regional uncorrected cortical CBF
Frontal* 22±5 21±5 20±4 19±4
Temporal*** 26±5 26±5 24±4 21±4a,b,c
Parietal*** 29±5 28±5 26±5 24±5a,d
PPC*** 38±7 37±7 34±6 31±6a,b
Occipital*** 35±7 34±6 32±7 29±7a,d
Cerebellum 26±5 26±6 25±6 25±5
Regional PVC cortical CBF
Frontal* 49±9 49±8 47±9 43±9
Temporal** 44±7 44±6 42±8 39±7a,d
Parietal*** 55±9 55±9 51±10 47±10a,d
PPC*** 63±11 62±10 58±11 55±11a,d
Occipital** 55±9 54±9 51±12 49±10a
Cerebellum 40±9 41±0 36±8 38±10
Results are given as mean ± standard deviation. If analysis of variance was p<0.05 a post-hoc Bonferroni test was
performed. Shown results are corrected for age and sex
*p<0.05, **p<0.01 and ***p<0.001
a p <0.05 compared to controls
b p<0.05 compared to stage-1 predementia patients
c p<0.05 compared to stage-2 predementia patients
d p<0.1 compared to stage-1 predementia patients
Stage 0: Aβ-/tau- patients with subjective complaints (SC), Stage 1: Aβ+/tau- patients with SC and mild
cognitive impairment (MCI), Stage 2: Aβ+/tau+ patients with SC andMCI, Stage 3: Aβ+/tau+ patients with AD
AD Alzheimer’s disease, PPC precuneus and posterior cingulated, PVC partial volume corrected
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Differences in regional CBF patterns
As expected, regional PVC cortical CBF values were
much higher than regional uncorrected cortical CBF
values, as the latter also contains cerebrospinal fluid
and maybe even some edges of whi te mat te r
(Table 2). A more advanced AD stage was related to
lower regional CBF in all regions except the cerebel-
lum. Relationships were most prominent in the tempo-
ral, parietal, PPC and occipital regions for uncorrected
cortical CBF, and in the parietal and PPC regions for
PVC cortical CBF (p for trend < 0.001; Fig. 1). Post-
hoc, uncorrected cortical and PVC cortical CBF were
lower in temporal, parietal, PPC and occipital regions
in AD dementia patients compared to controls
(Table 2). Furthermore, uncorrected cortical CBF was
lower in AD dementia patients compared to stage-1
predementia patients in the temporal, parietal (trend),
PPC and occipital (trend) regions, and compared to
stage-2 predementia patients in the temporal lobes. AD
dementia patients showed a trend towards lower PVC
cortical CBF values compared to stage-1 predementia
patients in the temporal, parietal, PPC and occipital re-
gions. No between-group CBF differences were found
in the frontal lobes and the cerebellum, and there were
no CBF differences between stage-2 predementia pa-
tients, stage-1 predementia patients and controls. Addi-
tional correction for WMH did not change the group
differences.
Relationship between CBF and cognition
Across groups, uncorrected whole brain CBF and PVC
cortical CBF were related to cognitive performance in
all brain regions, except the cerebellum (Table 3). When
we investigated correlations within each stage separate-
ly, in AD dementia patients this relationship was seen in
the temporal and parietal regions (uncorrected cortical
Fig. 1 Lower regional cerebral
blood flow (CBF) is associated
with advancing Alzheimer’s
disease (AD) stage. Bar graphs
display mean regional
uncorrected CBF (a) and mean
partial volume corrected (PVC)
cortical CBF (b) for the different
AD stages, per brain region. Error
bars represent standard deviations
(±2SD). Dose-response
relationships between CBF and
AD stage were detected using
general-linear models (AD stage
entered as a continuous measure),
resulting in a p for trend < 0.05 in
all brain regions except the
cerebellum. The most prominent
relationships between decreasing
CBF and advancing AD stage
were found in the posterior
supratentorial brain regions (p for
trend < 0.001). PPC precuneus
and posterior cingulate cortex.
*p for trend < 0.05,
**p for trend < 0.01,
***p for trend < 0.001
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and PVC cortical CBF; trends), and in the frontal lobes
(PVC cortical CBF; trend). Stage-2 predementia patients
showed a relationship between uncorrected CBF and
cognition in the occipital lobes (trend). After additional
adjustment for WMH (model 2), the essence of the re-
sults remained unchanged, with the addition that in
stage-1 predementia patients a relationship between cog-
nitive performance and uncorrected CBF in the occipital
lobes reached significance (standardized beta 0.70,
p<0.05).
Discussion
The main finding of this study was that lower CBF was ob-
served with more advancing stages of AD across the spectrum
from normal cognition to AD dementia. Furthermore, CBF
was related to cognitive performance across AD stages and
within the stage-3 AD group.
To date, several ASL studies have detected CBF decreases
in AD, most prominently in the bilateral parietal cortex and
the precuneus and posterior cingulate cortex [8, 21, 22]. Based
on the currently widely supported suggestion that neuronal
dysfunction occurs prior to the stage of clinical AD, the aim
of this study was to investigate ASL-measured CBF of Aβ
positive non-demented patients in different disease stages [5,
7]. This resulted in the finding that, compared to Aβ and tau
negative controls, ASL-CBF was decreased in AD dementia
patients, but not in predementia AD patients. Temporo-
parietal CBF was lower in AD dementia patients than in
stage-1 predementia patients, in particular for uncorrected cor-
tical CBF, but to a lesser extent also for PVC cortical CBF.
Stage-2 predementia patients showed no decreased CBF com-
pared to controls, but their CBF did not differ from AD de-
mentia patients either. In fact, quantitative CBF values of
stage-2 predementia patients were numerically in between
the CBF values of stage-1 predementia patients and stage-3
AD dementia patients. These findings are in accordance with
the idea that CBF alterations, as a sign of neuronal dysfunc-
tion, occur further along the disease process than the accumu-
lation of Aβ, but before the stage of clinical dementia.
This is the first study comparing ASL-measured CBF of
predementia AD stages with study groups based on CSF bio-
marker profiles [5–7]. Previous ASL studies investigating ce-
rebral perfusion in MCI detected parietal and medial temporal
hypoperfusion in a less prominent and widespread pattern
than the hypoperfusion found in AD compared to controls
[8, 21–26]. However, none of these studies reported amyloid
Table 3 Relationship between cerebral blood flow (CBF) and cognition (Mini-Mental State Examination scores)
Across groups Control Predementia AD
Stage 0 Stage 1 Stage 2 Stage 3
Uncorrected whole brain CBF 0.33** −0.01 0.22 −0.20 0.21+
PVC cortical CBF 0.27** −0.02 0.30 −0.21 0.19
Regional uncorrected cortical CBF
Frontal 0.23* −0.06 −0.03 0.05 0.18
Temporal 0.38** 0.02 0.22 −0.03 0.21+
Parietal 0.40 −0.01 0.22 0.16 0.24+
PPC 0.40** 0.03 0.28 −0.17 0.17
Occipital 0.34** 0.12 0.25§ −0.35+ 0.18
Cerebellum 0.09 −0.05 0.24 −0.30 −0.04
Regional PVC cortical CBF
Frontal 0.24* −0.07 0.18 −0.21 0.23+
Temporal 0.31** −0.02 0.26 −0.13 0.22+
Parietal 0.32** −0.02 0.41 −0.18 0.21+
PPC 0.29** 0.01 0.46 −0.28 0.16
Occipital 0.23* 0.04 0.44 −0.30 0.11
Cerebellum 0.08 −0.04 0.13 −0.05 0.02
*p<0.01, **p<0.001, + p<0.1; adjustment for age and sex (model 1)
§ A relationship between cognition and uncorrected CBF in the occipital lobes (standardized beta 0.70; p<0.05) was detected after additional adjustment
for white matter hyperintensities (Fazekas-scores; model 2)
Stage 0: Aβ-/tau- patients with subjective complaints (SC), Stage 1: Aβ+/tau- patients with SC and mild cognitive impairment (MCI), Stage 2: Aβ+/
tau+ patients with SC and MCI, Stage 3: Aβ+/tau+ patients with AD
AD Alzheimer’s disease, PPC precuneus and posterior cingulated, PVC partial volume corrected
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status of the MCI patients. This leaves room for the possibility
that other CBF-decreasing non-AD pathology caused regional
CBF changes in MCI, such as DLB, which has previously
been shown to also be related to severe CBF decreases [27,
28]. In our study, we therefore used biomarkers to define our
study groups, allowing us to examine changes in CBF across
the entire spectrum of AD.
In the current hypothetical biomarker models for AD, FDG-
PET is considered the main functional neuroimaging tool to
assess neuronal injury in terms of hypometabolism in AD [3, 4,
29]. Since glucose metabolism and perfusion are closely relat-
ed, ASL is a potential alternative for the visualization of cere-
bral and neuronal function [30–32]. However, the relationship
between perfusion and metabolism has not yet been thorough-
ly investigated in the predementia stages of AD. One PET
study by Drzezga et al. [33] found lower regional glucose
metabolism in Aβ-positive healthy controls compared to Aβ-
negative controls, suggesting a relationship between Aβ and
glucose metabolism. This is not consistent with our finding
that ASL-measured CBF did not change with the presence of
amyloid pathology in a very early stage of AD. Direct com-
parisons of FDG-PET measured glucose metabolism and
ASL-measured cerebral perfusion in predementia AD are
needed to clarify whether glucose metabolism and cerebral
perfusion are directly related or consecutive processes.
In a previous study we showed that cognitive performance
was related to ASL-measured CBF in AD [8]. In the current
study we also found this relationship within the AD dementia
group, albeit in fewer regions and less strong. This discrepan-
cy may be due to the fact that in the current study, AD patients
were selected based on CSF biomarkers in addition to clinical
diagnosis, possibly causing less variability in both cognition
and CBF within the AD dementia group compared to our
previous study, in which the AD population also contained
subjects with normal or borderline normal CSF Aβ and tau
values. Besides a trend towards a significant relationship be-
tween occipital CBF and cognition in the stage-2 predementia
group (in the unexpected direction), no relationships between
CBF and cognition were found in the Aβ positive
predementia groups. However, it is not inconceivable that a
lack of power contributed to this negative result. After adjust-
ment for WMH, a relationship between uncorrected CBF in
the occipital lobes and cognition did appear within the stage-1
predementia group.
This study has several strengths and limitations. First, the
study groups were selected based on both clinical diagnosis
and CSF biomarkers. This limited our sample sizes, but at the
same time resulted in quite homogeneous study groups,
strongly reducing the effect of perfusion changes caused by
for example neurodegeneration of non-AD origin. Since the
criteria for clinical stages in preclinical and prodromal AD
show strong similarities, and implementing all stages in a
sequential manner is not easily done, we chose to reduce the
number of study groups by combining preclinical and prodro-
mal patient groups with identical biomarker profiles. A quan-
titative 3D pseudo-continuous ASL sequence with whole-
brain coverage was used to study CBF. Furthermore, both
CBF without correction for partial volume effects (represen-
tative for clinical practice) and PVC cortical CBF (actual gray
matter CBF) were studied. The inclusion of subjects with sub-
jective complaints instead of healthy controls might be con-
sidered a limitation. However, controls were only included if
they had normal biomarkers, strongly decreasing the likeli-
hood that they would have preclinical AD. Additional poten-
tial limitations related to image technique include the fact that
ASL scan quality could not be assured completely. Although
the perfusion images were visually of good quality, the label-
ling efficiencywas not assessed formally. Furthermore, we did
not scan with several delay times to account for differences in
travel times between groups. However, in line with recently
published recommendations [14], a delay time of 2.0 s (in-
stead of 1.5 s) was used to alleviate the effect of delayed blood
arrival in the brain in our study groups [34].
In conclusion, we found lower CBF with advancing NIA-
AA-based stages of AD. Aβ-positive predementia patients
with normal CSF tau levels showed no reduction in ASL-
measured CBF, endorsing the idea that CBF changes are not
directly related to Aβ deposition. Furthermore, the continuing
decrease along the continuum of AD shows that the reduction
of CBF does not reach a bottom level, but is associated with
decline severity, suggesting that ASL-measured CBF may be
used as a measure for disease progression.
Acknowledgments The authors thank Ajit Shankaranarayanan of GE
Healthcare for providing the 3D pseudo-continuous ASL sequence that
was used to obtain data for this paper.
The scientific guarantor of this publication is Frederik Barkhof. The
authors of this manuscript declare relationships with the following com-
panies: M.A.A. Binnewijzend, M.R. Benedictus J.P.A. Kuijer and W.M.
van der Flier report no disclosures. C.E. Teunissen serves on the advisory
board of Innogenetics and Roche. She has received speaker honorarium
on a symposium organised by Teva. N.D. Prins serves on the advisory
board of Boehringer Ingelheim and Envivo. He has been a speaker at
symposia organised by Janssen and Novartis. NDP has a senior fellow-
ship at the Alzheimer Center of the VU University Medical Center
Amsterdam, partly supported by Vereniging AEGON and receives re-
search support from the Brain Foundation of The Netherlands and
Alzheimer Nederland. NDP receives no personal compensation for the
activities mentioned above. M.P. Wattjes serves as a consultant for
Biogen-Idec. Dr. Wattjes receives research support from Biogen Idec,
Bayer Healthcare, Roche and Janssen Cilag. Dr. Wattjes serves as an
editorial board member of European Radiology. B.N.M. van Berckel
receives research support from the Alzheimer Assistance Foundation,
the Center for Translational Molecular Imaging, the Alzheimer Associa-
tion, De Hersenstichting Nederland and the Internationale Stichting
Alzheimer Onderzoek. Dr. van Berckel receives no personal compensa-
tion from these organizations. P. Scheltens receives grant support (for the
institution; the Alzheimer Center of the VU University Medical Center
Amsterdam, see also below) from GE Healthcare, Danone Research and
MERCK. In the past 2 years he has received speaker's fees (paid to the
institution) from Lilly, GE Healthcare, Lundbeck, Danone and Jansen
512 Eur Radiol (2016) 26:506–514
AI-Pfizer. He is co-editor-in-chief of Alzheimer Research &Therapy. F.
Barkhof serves on the editorial boards of Brain, European Radiology,
Radiology, Multiple Sclerosis and Neuroradiology and serves as a con-
sultant for Bayer-Schering Pharma, Sanofi-Aventis, Biogen-Idec, TEVA,
Synthon BV, Merck-Serono, Jansen Research, Novartis and Roche. Dr.
Barkhof receives research support from the DutchMS Society (EU-FP7).
Dr. Barkhof has received consulting fees or honoraria for the consultancy
mentioned above. Dr. Barkhof has received speaker's fees from the
Serono Symposia Foundation.
The study was supported by the Alzheimer Center of the VU Univer-
sity Medical Center Amsterdam, The Netherlands. Research from the
Alzheimer Center of the VU University Medical Center Amsterdam is
part of the neurodegeneration research programme of the Neuroscience
Campus Amsterdam. The Alzheimer Center of the VU University Med-
ical Center Amsterdam is supported by Alzheimer Nederland and
Stichting VUmc funds. The clinical database structure was developed
with funding from Stichting Dioraphte.
One of the authors has significant statistical expertise (WM van der
Flier). Institutional Review Board approval was obtained. Written in-
formed consent was obtained from all subjects (patients) in this study.
Some study subjects or cohorts have been previously reported in:
a) Binnewijzend MA, Kuijer JP, Benedictus MR, van der Flier WM,
Wink AM, Wattjes MP et al. Cerebral blood flow measured with 3D
pseudocontinuous arterial spin-labeling mr imaging in alzheimer disease
and mild cognitive impairment: a marker for disease severity. Radiology
2013;267:221-30.
b) Binnewijzend MA, Kuijer JP, van der Flier WM, Benedictus MR,
Moller CM, Pijnenburg YA et al. Distinct perfusion patterns in
Alzheimer's disease, frontotemporal dementia and dementia with Lewy
bodies. Eur Radiol 2014;24:2326-33.
Methodology: retrospective, cross-sectional study, performed at one
institution.
Open Access This article is distributed under the terms of the
Creative Commons Attribution-NonCommercial 4.0 International
License (http://creativecommons.org/licenses/by-nc/4.0/), which per-
mits any noncommercial use, distribution, and reproduction in any medi-
um, provided you give appropriate credit to the original author(s) and the
source, provide a link to the Creative Commons license, and indicate if
changes were made.
References
1. Jack CR Jr, Lowe VJ, Weigand SD, Wiste HJ, Senjem ML,
Knopman DS et al (2009) Serial PIB and MRI in normal, mild
cognitive impairment and Alzheimer's disease: implications for se-
quence of pathological events in Alzheimer's disease. Brain 132:
1355–1365
2. Jagust WJ, Landau SM, Shaw LM, Trojanowski JQ, Koeppe RA,
Reiman EMet al (2009) Relationships between biomarkers in aging
and dementia. Neurology 73:1193–1199
3. Jack CR, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner
MWet al (2010) Hypothetical model of dynamic biomarkers of the
Alzheimer's pathological cascade. Lancet Neurol 9:119–128
4. Jack CR Jr, Knopman DS, Jagust WJ, Petersen RC, Weiner MW,
Aisen PS et al (2013) Tracking pathophysiological processes in
Alzheimer's disease: an updated hypothetical model of dynamic
biomarkers. Lancet Neurol 12:207–216
5. Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox
NC et al (2011) The diagnosis of mild cognitive impairment due to
Alzheimer's disease: recommendations from the National Institute
on Aging-Alzheimer's Association workgroups on diagnostic
guidelines for Alzheimer's disease. Alzheimers Dement 7:270–279
6. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR
Jr, Kawas CH et al (2011) The diagnosis of dementia due to
Alzheimer's disease: recommendations from the National Institute
on Aging-Alzheimer's Association workgroups on diagnostic
guidelines for Alzheimer's disease. Alzheimers Dement 7:263–269
7. Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan
AM et al (2011) Toward defining the preclinical stages of
Alzheimer's disease: recommendations from the National Institute
on Aging-Alzheimer's Association workgroups on diagnostic
guidelines for Alzheimer's disease. Alzheimers Dement 7:280–292
8. Binnewijzend MA, Kuijer JP, Benedictus MR, van der Flier WM,
Wink AM, Wattjes MP et al (2013) Cerebral blood flow measured
with 3D pseudocontinuous arterial spin-labeling MR imaging in
Alzheimer disease and mild cognitive impairment: a marker for
disease severity. Radiology 267:221–230
9. McKhann G, Drachman D, Folstein M, Katzman R, Price D,
Stadlan EM (1984) Clinical diagnosis of Alzheimer's disease: re-
port of the NINCDS-ADRDAWork Group under the auspices of
Department of Health and Human Services Task Force on
Alzheimer's Disease. Neurology 34:939–944
10. Petersen RC, Stevens JC, Ganguli M, Tangalos EG, Cummings JL,
DeKosky ST (2001) Practice parameter: early detection of demen-
tia: mild cognitive impairment (an evidence-based review). Report
of the Quality Standards Subcommittee of the American Academy
of Neurology. Neurology 56:1133–1142
11. Petersen RC (2004) Mild cognitive impairment as a diagnostic en-
tity. J Intern Med 256:183–194
12. Fazekas F, Chawluk JB, Alavi A, Hurtig HI, Zimmerman RA
(1987) MR signal abnormalities at 1.5 T in Alzheimer's dementia
and normal aging. AJR Am J Roentgenol 149:351–356
13. Dai W, Garcia D, de BC, Alsop DC (2008) Continuous flow-driven
inversion for arterial spin labeling using pulsed radio frequency and
gradient fields. Magn Reson Med 60:1488–1497
14. Alsop DC, Detre JA, Golay X, Gunther M, Hendrikse J,
Hernandez-Garcia L et al (2014) Recommended implementation
of arterial spin-labeled perfusion MRI for clinical applications: A
consensus of the ISMRM perfusion study group and the European
consortium for ASL in dementia. Magn Reson Med. doi:10.1002/
mrm.25197
15. Buxton RB, Frank LR, Wong EC, Siewert B, Warach S, Edelman
RR (1998) A general kinetic model for quantitative perfusion im-
aging with arterial spin labeling. Magn Reson Med 40:383–396
16. Smith SM (2002) Fast robust automated brain extraction. Hum
Brain Mapp 17:143–155
17. Jenkinson M, Smith S (2001) A global optimisation method for
robust affine registration of brain images. Med Image Anal 5:
143–156
18. Zhang Y, Brady M, Smith S (2001) Segmentation of brain MR
images through a hidden Markov random field model and the
expectation-maximization algorithm. IEEE Trans Med Imaging
20:45–57
19. Asllani I, Borogovac A, Brown TR (2008) Regression algorithm
correcting for partial volume effects in arterial spin labeling MRI.
Magn Reson Med 60:1362–1371
20. Mulder C, Verwey NA, van der Flier WM, Bouwman FH, Kok A,
van Elk EJ et al (2010) Amyloid-beta(1-42), total tau, and phos-
phorylated tau as cerebrospinal fluid biomarkers for the diagnosis of
Alzheimer disease. Clin Chem 56:248–253
21. Dai W, Lopez OL, Carmichael OT, Becker JT, Kuller LH, Gach
HM (2009) Mild cognitive impairment and alzheimer disease: pat-
terns of altered cerebral blood flow at MR imaging. Radiology 250:
856–866
22. Johnson NA, Jahng GH, Weiner MW, Miller BL, Chui HC, Jagust
WJ et al (2005) Pattern of cerebral hypoperfusion in Alzheimer
disease and mild cognitive impairment measured with arterial
Eur Radiol (2016) 26:506–514 513
spin-labeling MR imaging: initial experience. Radiology 234:851–
859
23. Bangen KJ, Restom K, Liu TT, Wierenga CE, Jak AJ, Salmon DP
et al (2012) Assessment of Alzheimer's disease risk with functional
magnetic resonance imaging: an arterial spin labeling study. J
Alzheimers Dis 31(Suppl 3):S59–S74
24. Chao LL, Buckley ST, Kornak J, Schuff N, Madison C, Yaffe K
et al (2010) ASL perfusion MRI predicts cognitive decline and
conversion from MCI to dementia. Alzheimer Dis Assoc Disord
24:19–27
25. Fleisher AS, Podraza KM, Bangen KJ, Taylor C, Sherzai A,
Sidhar K et al (2009) Cerebral perfusion and oxygenation
differences in Alzheimer's disease risk. Neurobiol Aging
30:1737–1748
26. Kim SM, Kim MJ, Rhee HY, Ryu CW, Kim EJ, Petersen ET et al
(2013) Regional cerebral perfusion in patients with Alzheimer's
disease and mild cognitive impairment: effect of APOE epsilon4
allele. Neuroradiology 55:25–34
27. Binnewijzend MA, Kuijer JP, van der Flier WM, Benedictus MR,
Moller CM, Pijnenburg YA et al (2014) Distinct perfusion patterns
in Alzheimer's disease, frontotemporal dementia and dementia with
Lewy bodies. Eur Radiol 24:2326–2333
28. Fong TG, Inouye SK, Dai W, Press DZ, Alsop DC (2011)
Association cortex hypoperfusion in mild dementia with Lewy
bodies: a potential indicator of cholinergic dysfunction? Brain
Imaging Behav 5:25–35
29. Frisoni GB, Fox NC, Jack CR Jr, Scheltens P, Thompson PM
(2010) The clinical use of structural MRI in Alzheimer disease.
Nat Rev Neurol 6:67–77
30. Chen Y, Wolk DA, Reddin JS, Korczykowski M, Martinez PM,
Musiek ES et al (2011) Voxel-level comparison of arterial spin-
labeled perfusion MRI and FDG-PET in Alzheimer disease.
Neurology 77:1977–1985
31. JueptnerM,Weiller C (1995) Review: doesmeasurement of region-
al cerebral blood flow reflect synaptic activity? Implications for
PET and fMRI. Neuroimage 2:148–156
32. Musiek ES, Chen Y, Korczykowski M, Saboury B, Martinez PM,
Reddin JS et al (2012) Direct comparison of fluorodeoxyglucose
positron emission tomography and arterial spin labeling magnetic
resonance imaging in Alzheimer's disease. Alzheimers Dement 8:
51–59
33. Grimmer T, Faust M, Auer F, Alexopoulos P, Forstl H,
Henriksen G et al (2012) White matter hyperintensities pre-
dict amyloid increase in Alzheimer's disease. Neurobiol
Aging 33:2766–2773
34. Campbell AM, Beaulieu C (2006) Pulsed arterial spin labeling pa-
rameter optimization for an elderly population. J Magn Reson
Imaging 23:398–403
514 Eur Radiol (2016) 26:506–514
